Literature DB >> 12692939

Successful aortic valve replacement in severe pancytopenia related to myelodysplastic syndrome.

Kazuhiro Kurisu1, Yoshie Ochiai, Takashi Kajiwara, Ryuji Tominaga.   

Abstract

We report a 60-year-old man with myelodysplastic syndrome (MDS) whose aortic valve was replaced successfully. He suffered from dyspnea on exertion and was confirmed by echocardiography and cardiac catheterization to have severe aortic stenosis. A peripheral blood examination showed pancytopenia and a bone marrow examination showed MDS with a subtype of refractory anemia with excess blasts. His preoperative neutrophil count was 468/mm3, hemoglobin 9.8 g/dl, and platelet count 27,000/mm3. We conducted aortic valve replacement (AVR) using a bioprosthesis in July 2001. Pre- and postoperatively, we injected granulocyte colony-stimulating factor to keep the neutrophil count at 2,000/mm3 or more. We also transfused platelet concentrate and infused tranexamic acid. Despite potential risks of infection and bleeding, the AVR involved no significant complications. Careful preoperative planning thus plays an important role in managing such cases.

Entities:  

Mesh:

Year:  2003        PMID: 12692939     DOI: 10.1007/BF02719174

Source DB:  PubMed          Journal:  Jpn J Thorac Cardiovasc Surg        ISSN: 1344-4964


  8 in total

1.  Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology.

Authors: 
Journal:  J Clin Oncol       Date:  1996-06       Impact factor: 44.544

2.  Successful coronary artery bypass grafting for a patient with myelodysplastic syndrome: report of a case.

Authors:  T Yamagishi; K Fuse; T Saito; M Kato; Y Misawa; O Kamisawa; N Hasegawa; T Kawashima
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

3.  International scoring system for evaluating prognosis in myelodysplastic syndromes.

Authors:  P Greenberg; C Cox; M M LeBeau; P Fenaux; P Morel; G Sanz; M Sanz; T Vallespi; T Hamblin; D Oscier; K Ohyashiki; K Toyama; C Aul; G Mufti; J Bennett
Journal:  Blood       Date:  1997-03-15       Impact factor: 22.113

4.  Investigation of coronary artery bypass grafting for a patient with myelodysplastic syndrome.

Authors:  Y Miyagi; S Yamauchi; S Suzuki; A Kitagawa; Y Masaki; M Gomibuchi; S Tanaka
Journal:  Ann Thorac Cardiovasc Surg       Date:  2001-08       Impact factor: 1.520

5.  A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes.

Authors:  Y Yoshida; K Hirashima; S Asano; F Takaku
Journal:  Br J Haematol       Date:  1991-07       Impact factor: 6.998

6.  Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions.

Authors:  V Casati; D Guzzon; M Oppizzi; F Bellotti; A Franco; C Gerli; M Cossolini; G Torri; G Calori; S Benussi; O Alfieri
Journal:  J Thorac Cardiovasc Surg       Date:  2000-09       Impact factor: 5.209

7.  Proposals for the classification of the myelodysplastic syndromes.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1982-06       Impact factor: 6.998

Review 8.  Myelodysplastic syndromes. Pathogenesis, diagnosis and treatment.

Authors:  P Noël; L A Solberg
Journal:  Crit Rev Oncol Hematol       Date:  1992       Impact factor: 6.312

  8 in total
  1 in total

1.  Minimally invasive mitral valve repair via right mini-thoracotomy in patient with myelodysplastic syndrome.

Authors:  Takura Taguchi; Hiroyuki Nishi; Kimihiro Kurose; Kohei Horikawa; Go Kanazawa; Toshiki Takahashi
Journal:  J Cardiothorac Surg       Date:  2018-05-18       Impact factor: 1.637

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.